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ABSTRACT Fungi cause disease in nearly one billion individuals worldwide. Only
three classes of antifungal agents are currently available in mainstream clinical use.
Emerging and drug-resistant fungi, toxicity, and drug-drug interactions compromise
their efficacy and applicability. Consequently, new and improved antifungal therapies
are urgently needed. In response to that need, we have developed NP339, a 2-kDa
polyarginine peptide that is active against pathogenic fungi from the genera
Candida, Aspergillus, and Cryptococcus, as well as others. NP339 was designed based
on endogenous cationic human defense peptides, which are constituents of the cor-
nerstone of immune defense against pathogenic microbes. NP339 specifically targets
the fungal cell membrane through a charge-charge-initiated membrane interaction
and therefore possesses a differentiated safety and toxicity profile to existing anti-
fungal classes. NP339 is rapidly fungicidal and does not elicit resistance in target
fungi upon extensive passaging in vitro. Preliminary analyses in murine models
indicate scope for therapeutic application of NP339 against a range of systemic and
mucocutaneous fungal infections. Collectively, these data indicate that NP339 can be
developed into a highly differentiated, first-in-class antifungal candidate for poorly
served invasive and other serious fungal diseases.
KEYWORDS antifungal agents, antifungal resistance, antifungal therapy, antimicrobial
peptides
Fungal diseases remain a significant area of unmet medical need globally and affectclose to one billion individuals worldwide. They range from mucosal infections to
serious life-threatening invasive fungal diseases (IFDs) and are mainly caused by fungi
from the genera Candida, Aspergillus, Cryptococcus, Pneumocystis, and Histoplasma and
mucormycetes (Mucorales). Staggeringly, mortality associated with fungal diseases is
comparable with that of tuberculosis and three times higher than that of malaria (1).
While superficial fungal infections can occur in relatively healthy individuals, IFDs pre-
dominantly affect immunosuppressed and critically ill individuals (e.g., solid organ
transplant recipients, cancer patients, and HIV patients). Paradoxically, some major
advances of modern medicine and some invasive procedures come at a cost of
increased IFD incidence (2).
Despite a major impact on human health, fungal diseases have failed to garner as
much attention from the policymakers and industry as other infectious diseases. For
instance, compared with over 15 classes of antibacterial drugs (3), only five classes of
antifungal agents are currently available, with only three of them in mainstream clinical
use (for reviews, see, e.g., references 4 and 5). Furthermore, the use of current antifun-
gals is often limited by adverse side effects (e.g., amphotericin B is nephrotoxic, and
azoles are hepatotoxic) (6, 7) and drug-drug interactions (e.g., interactions of statins
and fluconazole and interactions of posaconazole with some immunosuppressants) (8).
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Furthermore, these drugs can sometimes be fungistatic instead of fungicidal, which
drives the development of antifungal resistance (9).
Antifungal drug resistance is a major and multifactorial problem. First, in addition
to the fungistatic effect, the lack of tools for accurate and timely diagnosis of infection
necessitates prophylactic use and empirical therapy, risking prolonged exposure of the
pathogen to suboptimal concentrations of the drug, driving resistance development
(5, 10–12). Furthermore, since the available antifungals typically target a specific
enzyme or cellular pathway, the pathogen can become resistant by modifying or over-
expressing the drug target or by inducing the production of efflux pumps that remove
the drug from the cell (13). Cross-resistance to antifungal drugs has been observed
(14). In addition, agricultural and industrial fungicides that have a similar structure
and/or mechanism of action to those of drugs used in the clinic can also drive the evo-
lution of resistance (15–18). These issues not only limit the efficacy of drugs against
existing pathogens, but also shift the epidemiology toward the emergence of new
pathogens that are inherently resistant to currently available antifungal agents
(19–23). New antifungal molecules are therefore urgently needed to combat drug re-
sistance and emerging fungal pathogens.
To date, the majority of antifungal drug efforts have generally focused on the
improvement of existing molecule classes: e.g., reducing their toxicity, improving phar-
macodynamics and pharmacokinetics, enhancing their formulations, and increasing
specificity (4, 24). In contrast, we are focused on harnessing nature’s own defenses to
fight microbial infections. Specifically, we have been evaluating the antifungal poten-
tial of synthetic peptides inspired by endogenous host defense peptides (HDPs), which
are short (50 to 100 amino acids) cationic and amphipathic peptides that play a critical
“first responder” role in immune defense and have broad-spectrum antimicrobial activ-
ity (25–28).
Here, we present preliminary characterization of NP339, a 2-kDa polyarginine pep-
tide for the treatment of IFDs and other serious fungal infections. We show that NP339
has a broad spectrum of antifungal activity in artificial medium and biological matrices,
does not elicit resistance development in vitro, has an excellent in vitro safety and tox-
icity profile, and is well tolerated and shows initial efficacy in rodent models of fungal
diseases. NP339 is a promising candidate molecule representing a new class of therapy
for poorly served fungal infections.
RESULTS
Discovery of NP339, a polyarginine peptide with antifungal activity. HDPs are
naturally occurring defense peptides and a cornerstone of immunity. They act by elicit-
ing direct antimicrobial effects against microbes and/or immunopotentiation (27, 28).
We aimed to exploit only the HDP membrane-disrupting potential as a mechanism of
antifungal activity for a novel antimicrobial peptide. HDPs are highly evolutionarily
conserved and contain a high percentage (30 to 50%) of positively charged residues,
such as arginines and lysines. The peptides align, via these residues, with the nega-
tively charged microbial membrane and perturb it (27, 29). We asked what would hap-
pen if such a peptide would be stripped to contain only cationic residues (e.g., arginine
and lysine). Short, synthetic polyarginine peptides have already been developed as
cell-penetrating peptides to deliver various cargoes (drugs or dyes) to the mammalian
cell (30, 31), but to the best of our knowledge, their antifungal potential had not yet
been explored. We exposed Candida albicans to various cationic polypeptides gener-
ated by solid-phase synthesis as acetate salts (Table 1). While polylysines and short
peptides (Arg9 and shorter) did not kill the target cell, longer arginine chains within
the range expected from the cationic residue composition of endogenous HDPs, and
optimally with a molecular mass of approximately 2 kDa, had pronounced antifungal
activity. This was a novel observation, and we therefore proceeded to investigate the
antifungal activity of polyarginine peptides in more detail. We selected a 2-kDa polyar-
ginine peptide (henceforth referred to as NP339) for further, in-depth analysis.
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NP339 specifically targets the fungal cell membrane in a charge-dependent
manner. Cationic antimicrobial peptides interact with and disturb the microbial mem-
brane, while cell-penetrating peptides interact with the membrane without destroying
it. We therefore first confirmed the mode of NP339 antifungal activity.
Electron microscopy analysis indicated that, similar to one of the known functions
of endogenous HDPs, NP339 acts by causing cell lysis. As observed by transmission
electron microscopy (TEM), NP339 exposure resulted in the lysis of planktonic cells of
C. albicans (Fig. 1A). Specifically, exposure to 4mg/liter (1 MIC of NP339 against this
strain of C. albicans determined by standard methods of the Clinical and Laboratory
Standards Institute [CLSI]) (32) of NP339 resulted in rapid cell destruction within
30min: rupture of the cell membrane and wall, with the resulting loss of cellular con-
tents. This effect was not observed upon exposure to even 1 MIC of caspofungin or
human b-defensin 2, or double-distilled water (the control) for the same time period.
TABLE 1 Antifungal activity of polyarginine peptides








aMIC values against C. albicans NCTC 3179 are shown. The data are representative of one replicate.
bNP339.
FIG 1 NP339 destroys planktonic and biofilm-forming fungal cells. (A) C. albicans AM2003-0182 cells
were grown in 2 RPMI 1640 medium at 30°C for 1 h. The cells (1  108 CFU/ml) were exposed to
the indicated agents for 30min and analyzed by TEM. The doses tested were 4mg/liter NP339,
0.5mg/liter caspofungin, and 0.25mg/liter human b-defensin 2. The images are representative of at
least five fields of view. An arrow points to loss of cellular contents. An arrowhead points to the site
of cell membrane and cell wall rupture. (B) The indicated Aspergillus strains were grown in RPMI 1640
medium on a 0.2-mm-pore Whatman polycarbonate filter for 48 h at 35°C.The cells were exposed to
250mg/liter NP339 for 1 h and analyzed by SEM. The images are representative of at least two fields
of view. Arrows point to released cellular content. No released cellular content is visible in untreated
(control) samples.
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Furthermore, NP339 (33) appeared to also perturb the surface of and/or lyse biofilm-
forming Aspergillus cells, as indicated by cellular debris formed in the presence of
NP339, observed by scanning electron microscopy (SEM) (Fig. 1B).
Furthermore, to confirm the charge dependency of NP339 activity, we incubated
NP339 (at a concentration equivalent to the MIC as determined by standard CLSI meth-
ods) with polyanetholesulfonic acid (PASA), a negatively charged molecule that binds
to and effectively neutralizes the functional cationic charge of cationic compounds. We
then evaluated the effectiveness of PASA-preincubated peptide against C. albicans
(Fig. 2). As anticipated, preincubation with PASA dramatically reduced the fungicidal
activity of NP339. Specifically, while the MIC (4mg/liter) of NP339 killed C. albicans
within 30min of exposure, that time was extended to 60min for NP339 pretreated
with 0.5% PASA. Under saturated conditions (incubation of NP339 with .1% PASA),
NP339 activity was completely inhibited. These observations confirmed the criticality
of electrostatically mediated membrane interactions for NP339 activity. Of note, PASA
anionicity exceeds that of physiological salt concentrations, whereas the tissue culture
medium in which MIC assays were performed and in which NP339 is active is equiva-
lent to physiological salt conditions. We also show data (below) that NP339 retains ac-
tivity in human whole blood and saliva. Activity in the biological matrices and under
physiological salt conditions is a key element of NP339 that supports its viability as a
potential drug candidate, whereas a number of antimicrobial peptides investigated by
other groups have not had these essential properties (34, 35).
Since the interaction of NP339 with the fungal cell membrane is charge dependent,
we anticipated that the peptide would not interact, or at least interact differently, with
the mammalian cell membrane. That is because the lipid compositions, which affect
membrane charge and interactions with antimicrobial peptides (29, 36), of the fungal
and mammalian cell membranes are different. Accordingly, we labeled the C terminus
of NP339 with the fluorophore 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-inda-
cene-3-propionyl ethylenediamine (BODIPY FL EDA). BODIPY labeling did not affect
the antifungal activity of the peptide (data not shown). We then used fluorescence mi-
croscopy to evaluate the interaction between BODIPY-labeled NP339 and the fungal
and human peripheral blood mononuclear cells (PBMCs). As a control, we also BODIPY
labeled and tested the cell-penetrating peptide Arg9, which enters the mammalian cell
without destroying it (31). Indeed, while the BODIPY-labeled Arg9 peptide penetrated
both cell types tested, BODIPY-labeled NP339 only penetrated the fungal cell (Fig. 3).
These observations confirmed the specificity of NP339 for the fungal cell with no dis-
cernible host cell interaction.
NP339 has a broad antifungal activity, is rapidly fungicidal in vitro, and is
active in various biological matrices. We next investigated the spectrum of NP339
activity and compared its performance in vitro with that of standard-of-care antifun-
gals. Extensive screening revealed a broad spectrum of NP339 activity (see Table S1 in
FIG 2 Antifungal activity of NP339 is charge dependent. NP339 was incubated with different
concentrations of PASA for 30min at 37°C in sdH2O. C. albicans SC5314 cells were added to
pretreated NP339 and incubated for the indicated periods of time at 37°C. Afterwards, the cells were
plated and the resultant colonies counted. The data are presented as means 6 standard error (SE)
(n= 3).
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the supplemental material). The peptide was active against fungal pathogens from
such genera as Candida, Aspergillus, Cryptococcus, and Exophiala, as well as others. As a
caveat, the actual minimally active concentrations of NP339 might be much lower than
those determined using the standard CLSI and EUCAST antimicrobial susceptibility test
methods, which are designed for compounds with discrete intracellular targets and
therefore underestimate, or do not reflect at all, the apparent efficacy of membrane-
targeting antimicrobial agents such as antimicrobial peptides (AMPs) (37).
Furthermore, time-kill experiments with representative fungal pathogens revealed
that NP339 acted much more rapidly than the other antifungals tested (Table 2). For
example, NP339 concentration equivalent to 2 MIC (by CLSI methods) resulted in 3-
log reduction of C. albicans cell numbers after less than 1 h of exposure. In comparison,
it took 4 h for a caspofungin concentration equivalent to 4 MIC (by CLSI methods) to
achieve that effect. Of note, NP339 was as effective as amphotericin B and more effec-
tive than fluconazole and caspofungin against the emerging fungal pathogen Candida
auris. Furthermore, while NP339 did not kill Aspergillus fumigatus conidia as rapidly as
it did Candida cells, the killing was nonetheless more rapid than that elicited by the
other agents tested (Table 2). Overall, NP339 killed various fungal cells much more rap-
idly than existing antifungal agents.
We next asked about the activity of NP339 in biological matrices. Although the
growth media used for the time-kill determinations described above largely mimic
physiological salt concentrations, they do not reproduce the complexity of the infec-
tion site. Biological fluids also contain multiple charged compounds, such as amino
acids, proteins, and other substances (37) that could interact with and/or quench the
NP339 charge, affecting its activity. Accordingly, we investigated the activity of NP339
in human saliva and whole blood. First, we incubated C. albicans MD cells with 90% sa-
liva in the presence of different concentrations of NP339. Under these conditions,
C. albicans MD cells were rapidly killed by supra-MICs of NP339, with a 3-log reduction
in CFU/ml within 1 h (for 1,000mg/liter NP339) or 2 h (for 125 and 500mg/liter NP339)
(Fig. 4A). Furthermore, 125mg/liter NP339 prevented the attachment and biofilm for-
mation by C. albicans MD cells in flowing saliva experiments that mimic the conditions
in the oral cavity (Fig. 4B). These observations confirmed that NP339 is active in the
saliva.
FIG 3 NP339 specifically targets the fungal cell. C. albicans SC5314 and A. fumigatus AM2002/0066 cells were
prepared in RPMI 1640 medium, as described in Materials and Methods. PBMCs were isolated from fresh
human whole blood. The cells (1  105 CFU/ml) were mixed with 20mM BODIPY-labeled peptides and
incubated at 37°C for 1 h. The samples were then analyzed by optical and fluorescence microscopy. The
images are representative of three independent replicates.
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To test NP339 activity in the blood, we incubated A. fumigatus AM2002/0066 coni-
dia with human whole blood in the presence of different concentrations of NP339 and
quantified galactomannan antigen content in cultures as a readout of efficacy. NP339
exposure significantly reduced the galactomannan index (GI) in samples inoculated
with A. fumigatus, indicating that NP339 retains activity in blood (Fig. 4C). In addition,
while the blood became dark and clotted in the infected samples in the absence of
NP339, no such changes were apparent in the presence of NP339 (Fig. 4D). This further
confirmed successful killing of A. fumigatus by NP339 in whole blood. To our knowl-
edge, this is the first example of the antimicrobial activity of AMPs intended for sys-
temic administration being demonstrated ex vivo in “whole” human blood (dilution
factor from inoculum and peptide solution meaning 85% whole blood). Indeed, activity
was not retained but “improved” compared to MIC data obtained from culture media.
Importantly, the effective NP339 concentrations are not cytotoxic or hemolytic (see
below).
Collectively, the above observations indicate that NP339 has a broad antifungal ac-
tivity and is rapidly fungicidal in vitro. Furthermore, in addition to showing that NP339
is active under physiological salt conditions (see above), we showed that NP339 is also
active in complex biological matrices.
NP339 does not elicit development of cross-resistance in vitro. Exposure to anti-
fungal drugs drives fungal resistance development (14, 38). We therefore next asked
whether prolonged exposure to NP339 would induce anti-NP339 resistance in fungi.
We anticipated that that would be unlikely, considering the fungal membrane target-
ing and fungicidal mode of action of NP339.Accordingly, we passaged representative
strains of C. auris, C. albicans, Candida glabrata, and Candida tropicalis in media con-
taining sub-MICs (0.25 MIC) of NP339, caspofungin, fluconazole, or amphotericin B
(Table 3). The MIC values were determined every 5 passages, up to passage 30, and
fold changes from the starting value were calculated. The passaging induced flucona-
zole resistance in all strains tested, while the effect of caspofungin and amphotericin B
on the development of resistance was strain dependent. However, the passaging did
not induce NP339 resistance in any strain tested. In fact, the NP339 MIC against C. glab-
rata AM2007/0125 decreased with passaging.
In addition, where resistance developed for the standard-of-care therapies, we sub-
sequently tested the susceptibility of these strains to NP339. All strains remained




Time of kill (h)amg/liter ×MIC
C. albicans (n=2) NP339 4 2 0.5
Fluconazole 32 32 6
Caspofungin 1 4 4
C. auris (n=1) NP339 32 16 4
Amphotericin B 32 16 4
Fluconazole 256 16 48,
Caspofungin 16 16 6–24
A. fumigatus
Conidia (n= 2) NP339 256 16 2–4
Amphotericin B 2–8 4–16 48
Voriconazole 2–8 16 48
Posaconazole 4 16 24
Caspofungin 2–32 1–16 48
8-h germlings (n=2) NP339 32 2 2–4
aTime taken to kill 3 logs of Candida spp. (starting inoculum size 1 106 to 5 106 cells/ml), or 2 logs of A.
fumigatus conidia (starting inoculum size 1 105 cells/ml) and the same inoculum germinated for 8 h.
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susceptible to NP339, indicating that NP339 was effective even against strains with
newly acquired resistance to other antifungal agents (Table 4).
Collectively, these observations indicated that NP339 does not elicit resistance or
cross-resistance to standard-of-care antifungals in vitro.
NP339 is not cytotoxic or hemolytic in vitro. Having established the unique fungal
cell specificity of NP339, we next investigated the possible cytotoxic effects of NP339
FIG 4 NP339 is active in the human saliva and blood. (A) C. albicans MD cells were incubated in 90%
human saliva (final cell density of a 0.5 McFarland standard) and the indicated concentrations of
NP339 at 30°C. Samples were withdrawn at the specified time periods, plated on SAB agar, and
incubated at 30°C. The resultant cell growth (CFU/ml) is shown. The data are representative of the
mean 6 SE from triplicate experiments. (B) C. albicans MD cells were exposed to flowing 90% human
saliva, in the presence or absence of NP339 (125mg/liter), in a Fluxion BioFlux 200 (Fluxion, South
San Francisco, CA, USA) for 20 h at 37°C. Arrows indicate fungal cell clusters. Scale bar, 200mm. The
images are representative of triplicate experiments. (C) Citrated human whole blood was exposed to
A. fumigatus AM2002/0066 conidia (final density, 1  105 conidia/ml) for 24 h at 37°C, with or
without NP339. The GI was then determined in the sample supernatant (diluted 1:100 in sdH2O) by
ELISA. The ratio of GI in NP339-treated samples to that in NP339-untreated samples is shown. The
data are presented as means 6 standard deviation (n= 4) (*, P , 0.05, **, P , 0.01, and ***, P ,
0.001, versus no-NP339 control by one-way ANOVA with Dunnett’s multiple-comparison test). Dotted
line, 50% reduction in GI relative to sham-treated control. (D) Images of citrated human whole blood
incubated with A. fumigatus AM2002/0066 conidia, prepared as in panel C, after 48 h of incubation at
37°C, with or without 250mg/liter NP339 (top) or 500mg/liter NP339 (bottom). The images represent
multiple, consistent observations.
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on mammalian cells that would have been exposed to NP339 upon systemic adminis-
tration (the main mode of antifungal drug administration to individuals with IFD) (39).
We first exposed human PBMCs and the A549 epithelial lung cell line to concentrations
of NP399 that were hundreds of folds higher than those that elicit antifungal effects in
vitro (Fig. 5A and B) and determined the live/dead cell ratio using a commercial kit (see
Materials and Methods). NP339 was not toxic to these cells even at very high concen-
trations beyond any proposed therapeutic range.
We then evaluated the hemolytic potential of NP339. The percentage of hemolysis
of human red blood cells was negligible: approximately 1% hemolysis upon exposure
to up to 0.3mg/ml NP339 and approximately 2% hemolysis upon exposure to 0.6 to
5mg/ml NP339 (data not shown). In comparison, incubation with the detergent-posi-
tive control resulted in 100% hemolysis (data not shown).
Collectively, the above observations indicated a unique safety and toxicity profile of
NP339 as anticipated from a molecule of endogenous provenance.
Therapeutic efficacy potential of NP339 in vivo. Finally, we tested the therapeutic
potential of NP339 in vivo in murine models of fungal disease (Fig. 6). While we
observed a trend, but not a significant effect of NP339 administration on the fungal
kidney burden in the disseminated candidiasis model (Fig. 6A), there was a significant
improvement in the vaginal lavage burden (Fig. 6B) in the vaginal candidiasis model
and in the oral swab fluid burden in the oropharyngeal candidiasis model (Fig. 6C).
Similarly, nebulized NP339 reduced fungal lung burden in an invasive pulmonary
aspergillosis rodent model (Fig. 6D). Of note, the above evaluations were based on fun-
gal tissue burden determination by plating of homogenized tissue. As a caveat, this
method is best suited for assessing the efficacy of drugs internalized and retained by
the cell, not membrane-acting agents such as NP339. The peptide-fungal cell interac-
tion will be lost during tissue preparation for plating, resulting in an overestimation of
the actual fungal burden and hence, underestimation of peptide activity.
Overall, these preliminary observations from models not in any way optimized for
peptide therapeutics (mode of delivery, particularly for systemic administration, and
fungal burden analysis from tissue as endpoints) were encouraging and suggest the
therapeutic potential of NP339 in vivo. Further data will be generated in optimized
(i.e., determination of burden with appropriate methods) in vivo models of infection, in
TABLE 3 Effect of extensive passaging of Candida species in the presence of sub-MICs of
various antifungal compounds on the MICs of these compounds
Strain
Fold change in antifungal MIC at passage 30a
NP339 Caspofungin Fluconazole Amphotericin B
C. albicans SC5314 1 4 256 4
C. auris DSMZ1092 1 1 4 4
C. glabrata AM2007/0125 0.125 1 2 1
C. tropicalis AM2005/0568 1 8 256 4
aThe MIC of each compound tested at passage 0 was normalized to 1, and the fold change after 30 passages in
0.25MIC of each antifungal was calculated. A value of 1 signifies no change. The data are averages from three
independent replicates.
TABLE 4 Effect of extensive passaging of Candida species in the presence of sub-MICs of
various antifungal compounds on the NP339 MIC
Strain
Fold change in NP339 MIC at passage 30a
NP339 Caspofungin Fluconazole Amphotericin B
C. albicans SC5314 1 1 1 1
C. auris DSMZ1092 1 1 1 1
C. glabrata AM2007/0125 0.031 0.062 1 1
C. tropicalis AM2005/0568 1 1 1 1
aThe MIC of NP339 at passage 0 was normalized to 1, and the fold change in the MIC of NP339 after 30 passages
in 0.25MIC of the indicated antifungal was calculated. A value of 1 signifies no change. The data are averages
from three independent replicates.
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which antimicrobial peptide drugs such as NP339 can be tested more robustly (e.g.,
with the mode and frequency of systemic administration more representative of clini-
cal use, etc.).
DISCUSSION
We present our preliminary characterization of NP339, a synthetic 2-kDa polyargi-
nine peptide with broad antifungal activity. NP339 specifically targets the fungal cell
membrane, is rapidly fungicidal and active in various biological matrices, does not
induce resistance development in vitro, and shows initial evidence of efficacy in rodent
models of fungal disease. Therefore, it is a promising new candidate molecule for tar-
geting IFDs and other fungal infections.
The structure and mechanism of action of NP339 are unlike those of any existing
antifungal drug, as its design is inspired by HDP structure and function. Similar to
HDPs (27–29, 40, 41), the activity of NP339 is charge dependent, and the peptide only
targets the fungal cell membrane. Furthermore, the observation that NP339 did not
penetrate the mammalian cell is in agreement with the known properties of oligoargi-
nines. Futaki et al. (31) determined an apparent size cutoff for oligoarginine peptides,
FIG 5 NP339 is not cytotoxic. PBMCs (5  105 cells/ml) isolated from the human whole blood (A) and
A545 lung epithelial cells (monolayer) (B) were incubated with the indicated concentrations of NP339
for 2 or 3 h, respectively, in RPMI 1640 medium at 37°C. The numbers of surviving cells were
determined by LIVE/DEAD staining. The data are shown as means 1 SD (n= 2). The kill controls were
0.1% (vol/vol) Triton X-100 in panel A and 0.25% (wt/vol) SDS in panel B.
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above which the efficiency of penetrating the mammalian membrane decreases (9
amino acids). Accordingly, NP339 is .30% larger than the optimal translocating pep-
tide. Importantly, penetration does not equate to disruption, as the short polyarginine
peptide Arg9 penetrated both fungal and mammalian cells tested, yet did not destroy
these cells.
Development of fungus-specific drugs is challenging given the similarity between
the fungal and mammalian cells. Indeed, off-target effects often result in drug toxicity
(4, 24). NP339 specificity for the fungal cell is most likely associated with the different
lipid compositions of the fungal and mammalian cell membranes: while mammalian
membranes contain cholesterol, fungal membranes do not; the major sterol in the
fungal cell membrane is ergosterol (42, 43). Both cholesterol and ergosterol affect
membrane fluidity and permeability, as well as interactions with antimicrobial peptides
(29, 36, 44, 45).
FIG 6 Therapeutic effect of NP339 in murine models of fungal diseases. (A) Murine model of
disseminated candidiasis. CD1 male mice (n= 8/group) were infected with C. albicans FA6862
(approximately 1.1  104 CFU/mouse) by intravenous injection into the lateral tail vein. The indicated
agents were administered as specified. Fungal kidney burdens were assessed 29 h postinfection. (B)
Murine model of vaginal candidiasis. Female BALB/c mice (n= 8/group) were infected with C. albicans
529L (4.5  106 CFU/mouse) topically by intravaginal injection under temporary inhaled anesthesia.
The indicated agents were administered intravaginally. Fungal burdens in vaginal lavage samples
were determined after 3 days. (C) Murine model of oropharyngeal candidiasis. Male CD1 mice (n= 8/
group) were topically infected with C. albicans FA6862 (approximately 4.0  108 CFU/ml) under
temporary inhaled anesthesia. The indicated agents were then administered topically, unless
otherwise stated. Fungal burdens in the oral swab fluid were determined after 4 days. (D) Murine
model of invasive pulmonary aspergillosis. Immunosuppressed male CD1 mice (n= 8/group) were
infected by intranasal administration of A. fumigatus A1163 (7.2  104 CFU/mouse) under temporary
inhaled anesthesia. The indicated agents were then administered as specified. Fungal lung burdens
were determined at the clinical endpoint. In all panels, individual data points are presented with the
geometric mean (*, P , 0.05, and **, P , 0.01, by Mann-Whitney test). Administration mode: IP,
intraperitoneal injection; IV, intravenous injection; PO, oral administration. Administration frequency:
OD, once daily; BD, twice daily. Dotted horizontal lines identify the lower limit of detection in each
assay.
Duncan et al. Antimicrobial Agents and Chemotherapy














































Considering the specific mode of NP339 activity (i.e., charge-based interactions with
the fungal cell membrane), it was not surprising that this peptide was not cytotoxic in
vitro. Further, NP339 did not elicit a nonspecific immune response, as determined by
cytokine measurements in human whole blood exposed to the peptide (data not
shown). Indeed, we do not expect this polyarginine peptide to be immunogenic (i.e.,
to induce the production of antibodies). A related polyarginine compound that we
have developed, NP213, is not antigenic in rodents, and exposure does not lead to
antibody production, unless the peptide is conjugated to a model antigen, such as key-
hole limpet hemocyanin (KLH) (D. O’Neil, unpublished observation). Similarly, NP339
was well tolerated in mouse models of infection, further highlighting the lack of appa-
rent toxicity—at least at the therapeutic doses tested and duration of therapy used in
the present study. This highlights the potential of NP339 as a novel antifungal drug
candidate.
In addition, similar to HDPs (46), NP339 did not elicit resistance in vitro. The peptide
is rapidly fungicidal and targets the cell membrane, not a discrete intracellular target,
and kills by a “physical” interaction with membrane components resulting in mem-
brane lysis. In contrast, currently used antifungal drug classes are target molecule spe-
cific, and their use may promote resistance development, impeding therapeutic utility.
For instance, two classes of the currently used antifungals target specific molecules
within the fungal cell membrane: azoles (e.g., fluconazole) and polyenes (e.g., ampho-
tericin B) (5, 47). The former inhibits lanosterol 14a-demethylase, a key enzyme of the
ergosterol biosynthesis pathway encoded by CYP51 in filamentous fungi and ERG11 in
Candida spp., while the latter bind to ergosterol, thus disrupting the cell membrane.
Various resistance mechanisms to these drugs were reported and include mutations in
the target-encoding gene (48, 49), altered expression of the target enzyme (50–52), or
removal of the drug from the cell by efflux (53–55). Alternatively, antifungal drug use
may allow the growth of inherently less susceptible strains (56). Indeed, we observed
that while prolonged exposure to sub-MICs of some standard-of-care antifungals
induced resistance in the tested fungi, no such resistance to NP339 developed. Of
note, we did not observe NP339 cross-resistance in fungi that have acquired resistance
to other classes of antifungals. That is reassuring for an antifungal drug candidate, as
cross-resistance (e.g., resistance achieved by overexpression of efflux pumps or modifi-
cation of cell structures [57, 58]), would limit its utility.
Drug-drug interactions should be considered when devising novel antifungals.
Many of the currently used antifungal agents are processed in the liver, and their me-
tabolism is affected by hepatic active drugs and vice versa (59). This is especially well
documented for azoles: metabolic conversions of azoles are affected by coadministra-
tion of drugs that impact hepatic xenobiotic metabolism; conversely, azoles impair the
metabolism of some coadministered drugs by collaterally inhibiting human cyto-
chrome enzymes (60). For the former, rifampin (an antituberculosis drug) induces the
activity of hepatic cytochrome P450 (CYP450) enzymes; this accelerates the metabo-
lism of itraconazole and, consequently, decreases its antifungal activity (61). For the lat-
ter, inhibition of CYP450 34A by itraconazole inhibits the clearance of lovastatin (a cho-
lesterol-lowering drug), thus increasing the risk of skeletal muscle toxicity (62). In
contrast, exogenous peptides are not processed in the liver, which minimizes the risk
of the involvement of NP339 in adverse drug-drug interactions (63, 64). This bodes
well for its applicability in the most likely target patient population for NP339: i.e.,
chemotherapy and transplant recipients and otherwise immunocompromised and seri-
ously ill individuals already subject to polypharmaceutical interventions.
Finally, the observations in rodent models of fungal infections further confirmed
NP339 as an antifungal drug candidate. NP339 administration resulted in fungal bur-
den reduction in the vaginal and oropharyngeal candidiasis models, as well as in the
invasive pulmonary aspergillosis model. Of note, these effects were observed even
though the NP339 dose, mode of administration, and fungal burden detection (by plat-
ing of homogenized tissue) had not been optimized for peptide drugs.
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An important limitation of the current study is the inability to predict the actual
NP339 efficacy and performance for clinical application based on in vitro characteriza-
tion via traditional, often inappropriate, antimicrobial susceptibility tests performed in
tissue culture medium. Specifically, these methods used for MIC determinations under-
estimate the activity of membrane-targeting antimicrobial peptides, with the apparent
MIC values exceeding those of nonpeptide antimicrobials (37). Assays such as GI deter-
mination in blood are much more reflective of therapeutic potential. Furthermore, the
tested microbes might react differently to peptide exposure within a specific microen-
vironment within the host compared with under in vitro conditions. This underscores
the importance of peptide activity testing in biological matrices reflective of the infec-
tion site, such as the saliva, blood, etc. The above problems lead to under- or overesti-
mation of the actual antimicrobial peptide activity (41, 65–67). Conversely, metabolic
stability of therapeutic peptides and availability in vivo are difficult to predict (68–70).
The strength of this study is the determination of the rapid, cidal antifungal mode
of activity of a novel peptide therapy candidate and, for the first time, of peptide anti-
fungal activity in human whole blood (and other biological matrices) by nonculture
methods. The results of the current study strongly position NP339 as a novel antifungal
peptide candidate with a broad therapeutic potential.
In conclusion, the broad spectrum of activity, high specificity for the fungal cell, and
low apparent toxicity render NP339 an attractive drug candidate. We are currently
actively pursuing its further development for application against specific fungal
diseases.
MATERIALS ANDMETHODS
Reagents. NP339 is a 2-kDa polyarginine obtained by solid-phase synthesis (Almac Sciences,
Edinburgh, United Kingdom, and Polypeptide, Strasbourg, France) as a polyarginine acetate at .95%
purity. The purity of the preparation was checked by high-performance liquid chromatography. Unless
stated otherwise, NP339 was prepared as a 20-mg/ml stock in water. All other polyarginine peptides
tested were synthesized by Almac Sciences or PepScan (Lelystad, Netherlands) and assayed similarly to
NP339.
Fungi and growth conditions. All fungal strains tested are listed in Table S2 in the supplemental
material. For general handling and unless stated otherwise, all strains were cultured on Sabouraud dex-
trose (SAB) agar slants (Sigma-Aldrich, Dorset, United Kingdom) for the indicated times prior to experi-
ments: Candida strains were precultured at 35°C for 24 h, Aspergillus strains were precultured at 35°C for
48 h, Cryptococcus strains were precultured at 30°C for 24 h, Exophiala strains were precultured at 35°C
for 72 h, Scedosporium strains were precultured at 35°C for 72 h, and Mucorales strains were precultured
at 35°C for 48 h.
Electron microscopy. For the TEM analysis, an overnight culture of C. albicans AM2003-0182 was
diluted to a density of 1  108 cells/ml in 2 RPMI 1640 medium, and the mixture was incubated at
35°C for 1 h. The cells were then washed three times in sterile water and once in 0.01 M sodium phosphate
buffer. Next, 1ml of 1 MIC of NP339 (final concentration, 4mg/liter), caspofungin (final concentration,
0.5mg/liter), or human b-defensin 2 (final concentration, 25mg/liter) was added, and the incubation con-
tinued at 30°C for 30min. The cells were then fixed in 2.5% (vol/vol) glutaraldehyde and stored at 4°C
before analysis. For TEM analysis, the cells were dehydrated in an ethanol and acetone series before being
embedded in wax resin, stained with uranyl acetate/lead citrate stains to improve contrast, sectioned to a
90-nm thickness, and mounted onto copper grids for TEM analysis. TEM micrographs were acquired using
a JEM-1400 Plus JEOL transmission electron microscope. Microscopy was performed in the Microscopy
and Histology Core Facility at the University of Aberdeen (United Kingdom).
For the SEM analysis, 1ml of a suspension of 2  104 Aspergillus conidia was incubated in RPMI 1640
medium (Sigma) in a 24-well polystyrene plate containing a 0.2-mm-pore Whatman polycarbonate filter
for 48 h at 35°C. The medium was then removed, 1ml of RPMI 1640 medium containing 250mg/liter of
lipid-tagged NP339 was added, and the samples were incubated for 1 h at 30°C. The medium was
removed, 1ml of 2% (vol/vol) glutaraldehyde in 0.1 M sodium phosphate buffer was added, and the
samples were incubated for at least 12 h at 4°C to fix the cells. The filters were then removed, rinsed
three times with 0.1 M sodium phosphate buffer for 5min each, and placed in 1% (wt/vol) osmium te-
troxide in distilled H2O for 1 h. They were next washed three times with water for 5min each. The sam-
ples were dehydrated in a graded ethanol series (70, 80, and 90%, [vol/vol]) for 10min in each dilution
and then three times in 100% ethanol for 10min each. The filters were placed in hexamethyldisiloxane
(Sigma) for 10min and then left to dry overnight. All samples were mounted on aluminum stubs and
coated with gold. Images were acquired using a Zeiss EVO MA10 scanning electron microscope (Zeiss,
Cambridge, United Kingdom) at the Electron Microscopy Services Department at the University of
Aberdeen.
Charge neutralization experiments. The culture of C. albicans SC5314 was grown at 30°C overnight
and prepared to a 0.5 McFarland standard, as described for the time-kill experiments. For the
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experiment, 16% (wt/vol) PASA solution was prepared in sterile distilled H2O (sdH2O) and serially diluted
to final concentrations of 2, 4, 8, and 16%. Then, 250ml of NP339 solution in sterile distilled H2O (16 or
32mg/ml) was added to 250ml of PASA dilution, and the samples were incubated for 30min at 37°C.
Next, 500ml of the prepared cells was added, and the incubation continued at 37°C. Samples were
removed at 0, 0.5, 1, and 2 h, diluted in sterile water, plated on SAB agar, and incubated at 30°C for 24 h,
and the resultant colonies were counted.
Peptide specificity and penetration assays. The cell-penetrating peptide Arg9 was purchased from
Bachem AG (Bubendorf, Switzerland). The C termini of NP339 and Arg9 peptides were labeled with
BODIPY FL EDA in a reaction mixture containing 2mM peptide, 10mM BODIPY FL EDA, 10mM 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide, and 5mM N-hydroxysulfosuccinimide (all from Fisher Scientific
UK, Ltd., Loughborough, United Kingdom) in 0.1 M 2-(N-morpholino)ethanesulfonic acid buffer (MOPS;
pH 5.0) (Melford Laboratories, Ltd., Ipswich, United Kingdom) by stirring gently for 3 h at 25°C. Unbound
label and excess reagents were removed using SpinOUT GT-100 columns (Web Scientific, Ltd., Crewe,
United Kingdom), and the amount of peptide was quantified using a Micro BCA (bicinchoninic acid) pro-
tein assay kit (Fisher Scientific UK, Ltd.).
C. albicans SC5314 and A. fumigatus AM2002/0066 were grown for 24 or 48 h, respectively, on SAB
agar (Sigma) slants at 35°C. A. fumigatus AM2002/0066 cells were harvested from the slant into 0.15 M
NaCl (Fisher Scientific UK, Ltd.), and the conidia were isolated by passing through an EASYStrainer cell
sieve (70-mm pore; Greiner Bio-One, Gloucester, United Kingdom). They were then allowed to germinate
by inoculating 1  105 CFU/ml conidia into RPMI 1640 medium and incubating them at 25°C for 18 to
20 h. C. albicans SC5314 cells were harvested from the slant and then allowed to form hyphae by inocu-
lating 1  105 CFU/ml cells into RPMI 1640 medium and incubating them at 37°C for 4 h. PBMCs were
isolated from fresh human whole blood using Leucosep (Greiner Bio-One) tubes according to the manu-
facturer’s instructions and diluted to a concentration of 1  105 cells/ml in RPMI 1640. BODIPY-labeled
peptides (20mM) were added to 100ml of cells (PBMCs or fungi) in 16-well chamber slides (Thistle
Scientific, Ltd., Glasgow, United Kingdom) and incubated at 37°C for 60min. The samples were then ana-
lyzed by fluorescence and light microscopy using an Axiovert 40 CXL microscope (Carl Zeiss, Ltd.) with a
40 objective and filter set 10 (lEx = 450 to 490 nm; lEm = 515 to 565 nm) for fluorescence microscopy.
Cell images were captured after an 800-ms exposure.
MIC determinations. MIC values were determined following the CLSI-approved Reference Method
for Broth Dilution Antifungal Susceptibility Testing of Yeasts (approved standard M27-A3) (32) in RPMI
1640 medium (Sigma, Dorset, United Kingdom) at 35°C. For all filamentous fungi, the CLSI standard
M38-A2 (33) was followed, in RPMI 1640 medium at 35°C. Cell growth of all fungi was followed by meas-
uring the optical density at 530 nm (OD530) using the Powerwave XS plate reader (Biotek, Swindon,
United Kingdom). The MIC values are reported for the 24-h time point for Candida spp., Aspergillus spp.,
and Mucorales spp., for the 48-h time point for Cryptococcus spp., for the 48-h time point for
Scedosporium spp., and for the 72-h time point for Exophiala spp.
Time-kill assays in culture media. For Candida spp., the cells were grown for at least 18 to 24 h at
30°C, until visible growth was observed. The cells were then centrifuged and resuspended in sterile dis-
tilled H2O and diluted to the 0.5 McFarland standard density using 2 RPMI 1640 medium. The tested
antifungals were prepared at twice the required concentration. Then, 1ml of the inoculum was added to
1ml of the antifungal solution and incubated at 30°C. Every hour over the course of 8 h, 20ml of the cul-
ture was removed and 10-fold serial dilutions were prepared (from 1  1021 to 1  1027). Then, 50ml of
each dilution was plated on SAB agar (Sigma) in triplicate. The plates were incubated at 30°C until colo-
nies were observed on the control plates with vehicle-treated fungi. The colonies were counted, and the
percentage killed was determined based on the reduction in the number of CFU/ml in the treated sam-
ples compared with the vehicle-treated, untreated controls.
For A. fumigatus, a subculture was grown on a SAB agar (Sigma) slant for 72 h at 35°C until sporula-
tion. A. fumigatus cells were harvested from the slant into 0.15 M NaCl (Fisher Scientific UK, Ltd.), and
conidia were isolated by passing through an EASYStrainer cell sieve (70-mm pore; Greiner Bio-One,
Gloucester, United Kingdom) The conidial suspension was diluted to 1  105 CFU/ml in 2 antibiotic
medium 3 (Oxoid). For germling analysis, the conidial suspension was incubated for 8 h at 35°C prior to
analysis; for conidial experiments, it was used immediately. The experiment was performed as described
for Candida spp.
Time-kill assay in saliva. A subculture of C. albicans MD (oral isolate) was grown overnight at 30°C
on SAB medium. The cells were then resuspended in sterile deionized H2O and diluted to a density that
was 20 higher than the 0.5 McFarland standard. NP339 was prepared at 20 the required concentra-
tion in sterile distilled H2O. Human saliva was collected in the morning, prior to eating or brushing teeth,
and filter sterilized before use by passing through a 70-mm-pore EasyStrainer (Greiner Bio-One), followed
by passing through a 40-mm-pore EasyStrainer (Greiner Bio-One). The saliva was then sequentially sy-
ringe filtered through a 0.45-mm-pore filter and a 0.22-mm-pore filter. For each treatment, 50ml of 20
inoculum and 50ml of 20 NP339 were added to 900ml of filter-sterilized saliva, and the samples were
incubated at 30°C. At the specified time points, 10ml of the mixture was removed, and 10-fold serial dilu-
tions were prepared in sterilized distilled H2O, for a range of dilutions between 1  1022 and 1  1027.
Then, 50ml of each dilution was plated on SAB agar in triplicate. The plates were incubated at 30°C until
colonies were observed on control plates (untreated saliva-exposed cells). Colonies were counted, and
the percentage killed determined based on the reduction in CFU/ml in the treated samples relative to
the untreated controls.
BioFlux flow system experiments. C. albicans MD was grown at 30°C on SAB agar. The cells were
removed by taking a loopful and resuspending it in sterile water. The cells were then washed three times
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with sterile water and resuspended in RPMI 1640 tissue culture medium at a density of 1  107 cells/ml.
The BioFlux 200 system (Fluxion, South San Francisco, CA, USA) was primed with sterile RPMI 1640 prior
to the inoculation of cells. The cells were placed in the out-well of a 24-well BioFlux 200 plate, and a
pressure of 1 dyne was applied across the sealed plate from the out-well to the in-well for 10 s, until the
cells could be seen within the microfluidic chamber. The pressure was then removed, and the cells were
allowed to adhere for 1.5 h on a heated stage at 37°C. Human saliva from volunteers was centrifuged at
1,400 rpm for 5min to remove any debris and then passed through a 70-mm-pore EasyStrainer (Greiner
Bio-One), followed by passing through a 40-mm-pore EasyStrainer (Greiner Bio-One). The saliva was then
sequentially syringe filtered through a 0.45-mm-pore filter and a 0.22-mm-pore filter. The filter-sterilized
saliva was incubated at 30°C until use. NP339 (125mg/liter) was immobilized in 90% saliva. Once the
cells had adhered in the microfluidic chamber for 1.5 h, NP339 in 90% saliva was added to the in-well of
the BioFlux plate, placed on the heated stage at 37°C, and a pressure of 0.5 dyne was applied from the
in-well to the out-well for 20 h. The microfluidic channels were photographed every 5min to determine
biofilm formation.
GI determination. Human whole blood was obtained from healthy volunteers. A. fumigatus
AM2002/0066 conidia were harvested from mature cultures in phosphate-buffered saline (PBS). For the
experiment, citrated human whole blood was first mixed at a ratio of 9:1 with a suspension of A. fumiga-
tus AM2002/0066 conidia and then treated with different concentrations of NP339 prepared in PBS. This
resulted in a final concentration of 1  105 conidia/ml in 85% (vol/vol) blood. The mixtures (850ml of
blood, 100ml of inoculum, and 50ml of NP339) were incubated at 37°C for 24 h, resuspended by gentle
pipetting, and centrifuged at 1,500  g for 5min. The supernatant (plasma) was retrieved and diluted
1:100 in sdH2O before processing as per the Platelia galactomannan enzyme-linked immunosorbent
assay (ELISA) protocol (Invitrogen, Fisher Scientific UK, Ltd.). The GI was calculated using kit standards,
and GI data were normalized to those of the PBS sham-treated control (71).
Resistance development experiments. Antifungals were prepared at 0.5 MIC in sterile distilled
H2O and stored at 220°C for the duration of the assay. The fungal inoculum was prepared according to
the CLSI standard M27-A3 (32). For the analysis, 100ml of the antifungal stock was added to a 96-well
polystyrene plate in triplicate. Then, 100ml of the inoculum was added, for the final antimicrobial con-
centration of 0.25 MIC. Every 24 h, the sample OD530 was measured using Powerwave XS plate reader
(Biotek). If DOD530, calculated as the difference between treated and untreated (medium-only) samples,
exceeded 0.1, the culture was passaged by dilution to the CLSI standard inoculum in 2 RPMI 1640 me-
dium and mixed with 100ml of the 0.5 MIC solution of the antifungal. The passaging was repeated 30
times. Every five passages, a full MIC analysis was done, as specified above. After 30 passages, a full
NP339 MIC analysis was done for all strains, including those that had developed resistance to antifungal
agents other than NP339.
NP339 cytotoxicity. PBMCs were isolated from fresh human whole blood using Leucosep tubes
(Greiner Bio-One), according to the manufacturer’s instructions. The cells were suspended in RPMI 1640
medium (5  106 cells/ml) and transferred to 96-well plate (5  105 cells/well). NP339 solutions were
prepared in prewarmed RPMI 1640 medium and added to the cell suspension. The plates were incu-
bated at 37°C under 5% CO2 for 2 h. Toxicity was determined using the Molecular Probes LIVE/DEAD
Viability/Cytotoxicity kit (Fisher Scientific UK, Ltd.). As the kill control, 0.1% (vol/vol) Triton X-100 was
used. Untreated cells were the live control.
Lung epithelial cells (A549 cells; ATCC [distributed by LGC Promochem, Teddington, United
Kingdom]) were cultured in a 96-well plate in Ham’s F-12K medium (Fisher Scientific UK, Ltd.) supple-
mented with 10% (vol/vol) fetal bovine serum. The cells were incubated under 5% CO2 at 37°C until 90%
confluent. NP339 solutions and 0.25% SDS (the kill control) were prepared in prewarmed RPMI 1640 me-
dium. Once the cells reached 90% confluence, the culture medium was removed from the 96-well plate,
taking care not to disturb the cells, and 100ml of NP339 solution was added to the cell monolayer. The
plates were incubated at 37°C under 5% CO2 for 3 h. Toxicity was determined using the Molecular
Probes LIVE/DEAD Viability/Cytotoxicity kit, as per the manufacturer’s instructions. As the kill control,
0.25% (wt/vol) SDS was used. Untreated cells were the live control (cells incubated with the medium).
Hemolysis assay. The hemolysis assay was performed in 96-well V-bottom microplates. Stock solu-
tions of NP339 were prepared at twice the required maximum concentration in Hanks’ balanced salt so-
lution (HBSS; Fisher Scientific UK, Ltd.). A positive control of sterile H2O and a negative control of HBSS
were also prepared. Human whole blood was obtained from healthy volunteers by a trained phleboto-
mist. The blood samples were centrifuged at 800  g for 15min, and the plasma and PBMC layer were
removed. Red blood cells were then washed with Dulbecco’s PBS (DPBS; Fisher Scientific UK, Ltd.) and
centrifuged at 400  g for 15min. The DPBS layer was removed, and the process was repeated until the
supernatant became clear after the centrifugation. For the experiment, 200ml of a solution of a double
the desired concentration of NP339 was added to the first row of a V-bottom 96-well plate and serially
diluted down the plate with 100ml of HBSS, resulting in 100ml of double-strength test solution in each
well. Next, 1ml of red blood cell suspension was added to 10ml of DPBS; 100ml of the diluted red blood
cell preparation was then added to each well. The plate was incubated for 3 h at 37°C under 5% CO2.
Following the incubation, the supernatant was transferred to a fresh flat-bottom 96-well plate, and the
sample OD578 was read using a Biotek Powerwave XS plate reader (Biotek). The hemolysis percentage
was calculated as (expOD 2 negOD)/(posOD 2 negOD), where expOD is the mean experimental OD,
negOD is the mean negative-control OD, and posOD is the mean positive-control OD.
In vivo models of infection. In all experiments, the animals were housed 4 or 5/cage in sterilized
individual ventilated cages exposing the mice at all times to HEPA-filtered sterile air. Food and water
were available ad libitum, and sterile aspen chip bedding was changed at least once weekly. The room
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temperature was 22 6 1°C, with a relative humidity of 60% and maximum background noise of 56 dB.
Mice were exposed to 12-h light/dark cycles. Before the experiments, the animals were randomly di-
vided into groups. After the experiments, the animals were sacrificed by humane euthanasia by deliver-
ing 0.5ml of 200mg/ml pentobarbital solution via intraperitoneal injection. For quantification of fungal
burden, samples were diluted appropriately and then quantitatively cultured on to SAB containing
0.05mg/ml chloramphenicol and incubated at 37°C for 24 to 48 h before enumeration.
(i) Murine model of systemic candidiasis.Male CD1 mice (n= 24 mice, 6 to 8weeks of age, average
weight of 23.5 g) were obtained from Charles River, Margate, United Kingdom. All mice were infected
with C. albicans FA6862 (approximately 1.1  104 CFU/mouse in 0.2ml) by intravenous injection into the
lateral tail vein. The mice were randomly divided into three groups (n= 8/group): the control group (10
ml/kg of body weight 0.9% saline administered intravenously twice daily), the NP339 group (NP339 in
0.9% saline administered intravenously in 10ml/kg at 3mg/kg twice daily), and the caspofungin group
(drug in 0.9% saline administered intraperitoneally in 10 ml/kg at 1 mg/kg once daily). Caspofungin was
from Merck Sharp & Dohme, Ltd., Hertfordshire, United Kingdom. The mice were culled 29 h postinfec-
tion, and fungal kidney burdens were determined by plating as previously described.
(ii) Murine model of vaginal candidiasis. Female BALB/c mice (n= 24 mice, 6 to 8weeks of age,
weight of 16 to 18 g) were obtained from Charles River, Margate, United Kingdom. All mice were topi-
cally infected with C. Albicans 529L (4.5  106 CFU/mouse in 0.025ml) by intravaginal injection under
temporary inhaled anesthesia (2.5% isoflurane for 3 to 4 min). The mice were randomly divided into
three groups (n= 8/group): the control group (0.05ml of 65% [vol/vol] polyethylene glycol [PEG] 14000
administered vaginally once daily), the NP339 group (0.05ml NP339 in 65% [vol/vol] PEG 14000 adminis-
tered in sterile distilled water at 1mg/kg vaginally once daily), and the clotrimazole group (0.05ml, as
purchased at 1% [wt/vol], administered vaginally once daily). Clotrimazole (Canetsen) was from Bayer,
Leverkusen, Germany. At 3 days postinfection, fungal burdens in vaginal lavage samples were deter-
mined as described above.
(iii) Murine model of oropharyngeal candidiasis.Male CD1 mice (n= 24 mice, 6 to 8weeks of age,
average weight of 24.6 g) were obtained from Charles River, Margate, United Kingdom. All mice were
infected with C. albicans FA6862 (approximately 4.0 108 CFU/mouse topically in the oral cavity via
20min of exposure to a swab soaked in the fungal suspension), under temporary inhaled anesthesia (1.5
to 2% isoflurane). The mice were randomly divided into three groups (n= 8/group): the control group
(;0.1ml of PEG 300-soaked swab administered topically [oral application with a 10-min exposure
administered with a swab under anesthesia] once daily); the NP339 group (NP339 in PEG 300 adminis-
tered topically at 1mg/kg once daily), and the fluconazole group (drug administered orally at 5mg/kg
once daily). Fluconazole was from Pfizer UK, Tadworth, United Kingdom. At 4 days postinfection, fungal
burdens in swab fluid were determined by plating as described before.
(iv) Murine model of invasive pulmonary aspergillosis.Male CD1 mice (n= 24 mice, 8 to 10weeks
of age, average weight of 27.0 g) were obtained from Charles River, Margate, United Kingdom. Before
the experiment, the mice were immunosuppressed, as follows: days 24 to 11, subcutaneously injected
with ceftriaxone (50mg/kg), prepared as a 5-mg/ml solution in sterile saline for injection; days –4 and
–1, intraperitoneally injected with cyclophosphamide (150mg/kg), prepared as a 20-mg/ml solution
dosed at 7.5ml/kg in sterile saline for injection; and day –1, subcutaneously injected with 175mg/kg cor-
tisone acetate, prepared as a 17.5-mg/ml solution in sterile PBS–0.05% Tween 80. On day 0, all mice
were infected with A. fumigatus A1163 (7.2  104 CFU/mouse in 0.04ml) by intranasal administration
under anesthesia (2.5% isoflurane for 3 to 4 min). The mice were randomly divided into three groups
(n= 8/group): control (nebulized WFI administered twice daily for 10min), the NP339 group (nebulized
NP339 in WFI administered at 5mg/kg, twice daily), and the AmBisome group (AmBisome in 5% glucose
infusion solution [Baxter] administered intravenously in 10 ml/kg at 5mg/kg once daily). AmBisome was
from Gilead Sciences, Inc., San Dimas, CA. Fungal lung burdens were determined at the clinical endpoint
as previously described.
Ethical statement. Written informed consent was obtained for the provision of whole blood from
all volunteer donors. All animal experiments were performed by a third party contractor under UK Home
Office License.
Statistical analysis. Unless otherwise stated, all experiments were prepared at least in triplicate
with three technical replicates. All statistical analyses were performed using GraphPad Prism v7 or higher
(GraphPad Software, San Diego, CA). Statistical significance of in vivo data was assessed by Mann-
Whitney analyses relative to vehicle-treated control. One-way analysis of (ANOVA) with Dunnett’s multi-
ple-comparison test was used to analyze GI data. A P value of #0.05 was considered to indicate statisti-
cal significance.
Data availability. All data are presented in the manuscript and the associated supplemental mate-
rial files.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
SUPPLEMENTAL FILE 1, PDF file, 0.6 MB.
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